Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

Zevra Therapeutics (NasdaqGS: ZVRA) submitted U.S. Patent No. 11,707,456 for MIPLYFFA (arimoclomol) to the FDA for Orange Book listing.

Rhea-AI Summary

Zevra Therapeutics (NasdaqGS: ZVRA) submitted U.S. Patent No. 11,707,456 for MIPLYFFA (arimoclomol) to the FDA for Orange Book listing. The patent expires November 19, 2041, aiming to strengthen exclusivity for treating Niemann-Pick disease type C.

A separate patent term extension request for U.S. Patent No. 11,045,460, currently expiring in 2029, remains pending with the U.S. Patent and Trademark Office.

Positive

• Submission of MIPLYFFA U.S. Patent No. 11,707,456 for Orange Book listing, expiring in 2041
• Potentially longer U.S. market exclusivity window for MIPLYFFA in Niemann-Pick disease type C

Negative

• None.

Argus Jun 8 session

+13.95% close to close Open Argus

Details

News Market Reaction – ZVRA

On Jun 8, the day this news came out, ZVRA closed 13.95% above the previous close.

Data tracked by StockTitan Argus for the Jun 8 session.

Market Context

On Jun 8, the day this news came out, the stock closed 13.9% above the previous close. A strong posi...

Analysis

On Jun 8, the day this news came out, the stock closed 13.9% above the previous close. A strong positive reaction aligns with the strategic importance of longer MIPLYFFA exclusivity. The Orange Book listing for a patent expiring on November 19, 2041 materially extends the branded window versus the existing 2029 patent. Historically, even robust Q1 2026 results saw a -2.22% move, so sustained strength around this IP event would have contrasted with prior muted trading around fundamentally positive developments.

Key Figures

MIPLYFFA patent expiry: November 19, 2041 Existing patent expiry: 2029 MIPLYFFA patent number: U.S. Patent No. 11,707,456 +1 more

MIPLYFFA patent expiry

November 19, 2041

U.S. Patent No. 11,707,456 listed for Orange Book

Existing patent expiry

2029

U.S. Patent No. 11,045,460 prior to term extension

MIPLYFFA patent number

U.S. Patent No. 11,707,456

Submitted to FDA for Orange Book listing

Earlier patent number

U.S. Patent No. 11,045,460

Subject to pending patent term extension request

Historical Context

5 past events · Latest: May 29

5 events

1. May 29

   Inducement grants

   24h Move

   -0.9%

   Stock options granted to new employees under inducement award plan.

2. May 12

   Conference participation

   24h Move

   +2.3%

   Announcement of presentation at H.C. Wainwright BioConnect conference.

3. May 06

   Earnings and update

   24h Move

   -2.2%

   Q1 2026 financial results with strong revenue and pipeline progress.

4. Apr 22

   Earnings call notice

   24h Move

   +1.9%

   Details on upcoming Q1 2026 results release and conference call.

5. Mar 20

   CFO inducement grant

   24h Move

   +2.1%

   Equity award to new CFO including stock options with four-year vesting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

orange book, approved drug products with therapeutic equivalence evaluations, therapeutic equivalence, patent term extension, +2 more

6 terms

orange book regulatory

"submitted U.S. Patent No. 11,707,456 for MIPLYFFA to the U.S. Food and Drug Administration for listing in the publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book."

A publicly maintained FDA database that lists approved prescription drugs and notes which versions are considered interchangeable with brand-name products, along with key patent and exclusivity dates. Think of it as a product roster plus an expiration calendar: investors use it to see when a drug’s protection ends and generic competition can enter, which can directly affect a company’s sales, future revenue and stock value.

approved drug products with therapeutic equivalence evaluations regulatory

"for listing in the publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book."

A publicly maintained compilation of medicines that have been authorized for sale, paired with assessments indicating whether different versions of the same drug are considered clinically equivalent and interchangeable. Investors watch these evaluations because they determine when lower‑cost generic rivals can enter the market, affect pricing and market share, and signal patent or regulatory barriers that influence a drug maker’s revenues and competitive risk — like a product scoreboard that shapes future cash flow.

therapeutic equivalence medical

"Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book."

When two medicines produce the same clinical effect and safety for patients when used as intended, they are considered therapeutically equivalent. For investors, therapeutic equivalence matters because it determines whether a lower‑cost product (often a generic) can replace a branded drug without loss of effectiveness, directly affecting market share, pricing pressure, reimbursement and future sales; think of it like two interchangeable light bulbs that provide the same brightness but at different prices.

patent term extension regulatory

"The Company has also previously applied for a patent term extension for U.S. Patent No. 11,045,460"

A patent term extension is an official lengthening of the time a company has exclusive legal rights to sell a product, granted to compensate for delays in getting government approvals. For investors, it matters because extra years of exclusivity can sustain higher sales and profits by delaying generic or competitor entry—think of it as extending a short-term lease on a storefront so the original tenant keeps sole access to the customers longer.

u.s. patent and trademark office regulatory

"patent term extension remains pending with the U.S. Patent and Trademark Office"

The U.S. Patent and Trademark Office is the federal agency that reviews and grants patents and registers trademarks, like a land office that issues official property deeds for inventions and brand names. For investors, its decisions matter because patents and trademarks can create legal protection and exclusive market rights that boost a company’s revenue potential, reduce competition, and change risk and valuation dynamics.

niemann-pick disease type c medical

"people living with Niemann-Pick disease type C (NPC), an ultra-rare, progressive, and devastating neurodegenerative disease"

A rare inherited disorder in which cells cannot move cholesterol and other fats properly, causing them to build up like a clogged waste line and leading to progressive neurological problems, liver dysfunction, and variable symptoms that can appear from infancy to adulthood. It matters to investors because effective treatments are limited, so drug candidates can attract strong regulatory incentives, premium pricing and focused patient populations, but clinical development is small, risky and uncertain.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041

Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that it has submitted U.S. Patent No. 11,707,456 for MIPLYFFA® (arimoclomol) to the U.S. Food and Drug Administration for listing in the publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The patent expires on November 19, 2041.

“We are pleased to further strengthen our intellectual property protection for MIPLYFFA with the listing of this patent in the FDA’s Orange Book,” said Neil F. McFarlane, Zevra's President and Chief Executive Officer. “MIPLYFFA represents an important therapeutic option for people living with Niemann-Pick disease type C (NPC), an ultra-rare, progressive, and devastating neurodegenerative disease with significant unmet need. This listing reflects our continued focus on maintaining and enhancing the intellectual property portfolio supporting MIPLYFFA as we work to maximize its long-term value and support patients and families affected by NPC.”

The Orange Book lists patents and regulatory exclusivities associated with brand-name drugs, which dictates when generic competitors can legally enter the market.

The Company has also previously applied for a patent term extension for U.S. Patent No. 11,045,460 which currently expires in 2029 and is awaiting a determination from the U.S. Patent and Trademark Office.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Caution Concerning Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026 and Zevra’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 6, 2026, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

Investor Contact

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com  

Media Contact

Julie Downs
+1 (508) 246-3230 
jdowns@zevra.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zevra Therapeutics (ZVRA) announce about MIPLYFFA patent protection on June 8, 2026?

Zevra announced it submitted a MIPLYFFA patent to the FDA for Orange Book listing, with protection to 2041. According to Zevra, U.S. Patent No. 11,707,456 expires November 19, 2041, supporting long-term exclusivity for MIPLYFFA in Niemann-Pick disease type C.

How long could MIPLYFFA (arimoclomol) be protected by the new U.S. patent for Zevra Therapeutics?

MIPLYFFA’s newly listed U.S. Patent No. 11,707,456 is set to expire on November 19, 2041. According to Zevra, this patent is being submitted for FDA Orange Book listing, which helps define when generic competitors may legally enter the U.S. market.

What is the significance of Orange Book listing for Zevra Therapeutics’ MIPLYFFA (ZVRA)?

Orange Book listing links MIPLYFFA’s patents to its approved drug product, influencing generic entry timing. According to Zevra, listing U.S. Patent No. 11,707,456 in the Orange Book is intended to strengthen intellectual property protection and support MIPLYFFA’s long-term value.

Which patents cover MIPLYFFA for Zevra Therapeutics and what are their current expiry dates?

MIPLYFFA is associated with U.S. Patent No. 11,707,456 expiring November 19, 2041, and U.S. Patent No. 11,045,460 expiring in 2029. According to Zevra, a patent term extension for the 11,045,460 patent has been filed and is still pending.

What is the status of Zevra Therapeutics’ patent term extension request for MIPLYFFA in the U.S.?

Zevra’s patent term extension request for U.S. Patent No. 11,045,460 is currently pending with the U.S. Patent and Trademark Office. According to Zevra, this patent presently expires in 2029, and the company is awaiting a determination on the extension application.

How does MIPLYFFA address Niemann-Pick disease type C for Zevra Therapeutics shareholders?

MIPLYFFA is described as an important therapeutic option for Niemann-Pick disease type C, an ultra-rare neurodegenerative disorder. According to Zevra, strengthening the intellectual property portfolio around MIPLYFFA aims to maximize its long-term value while supporting patients and families affected by NPC.